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Maria Lourdes del Río Solá, MD, Ruth Fuente Garrido, MD, Vicente Gutiérrez Alonso, MD, and
Carlos Vaquero Puerta, MD, Valladolid, SpainAbout 50 years ago, the etiology of most superior vena cava (SVC) obstruc-
tions was infectious in nature. Later, malignant diseases were the predominant
cause of SVC obstruction, in 90% of the cases. At present, 35% of SVC
obstructions are caused by the increased use of intravascular devices such as
catheters and pacemaker wires.1,2
We present the case of 67-year-old female patient who was admitted after
presenting with a syncopal episode that was associated with swelling and
congestion of the upper half of her body. The patient gave a history of edema
that had dramatically worsened in the ensuing 24 hours.
She had a history of a colonic tumor, treated with surgical extirpation and
adjuvant chemotherapy, which had recently recurred in both liver and lungs,
The patient was undergoing a new cycle of palliative chemotherapy through
a central venous port system. She also gave a history of subclavian vein throm-
bosis that had been treated with oral anticoagulants that had been stopped
3 months before.
The venous Doppler examination showed patency of both jugular veins
and a signiﬁcant increase of the venous tension in right jugular vein. An emer-
gency computed tomography scan showed a complete thrombosis of the
superior cava vein, with a thrombus extension to the left subclavian vein
and right atrium (A; Cover). This was also conﬁrmed using venous magnetic
resonance angiography (B).
An endovascular approach was planned for this patient. The procedure
was performed in the operating theater under local anesthesia and sedation.
Four Wallstents (18  60 mm, 16  60 mm, 16  20 mm, and 14 
60 mm; Boston Scientiﬁc, Natick, Mass) were placed from the right internal
jugular vein to the SVC. The intraoperative imaging showed patency of the
devices (C). There was an immediate improvement of the skin color, and
the patient reported symptomatic relief. She was discharged 2 days later
with anticoagulant medication.
The management of SVC syndrome associated with malignant disease
involves treatment of the cancer and alleviating the obstructive symp-
toms. Survival of patients with malignancies associated with SVC
syndrome does not appear to differ signiﬁcantly from the survival of
patients with the same tumor without SVC obstruction.3 The intravas-
cular stent placement achieved quicker symptomatic relief than irradiation
or chemotherapy.4the University Hospital of Valladolid.
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